

POST-CONGRESS REPORT

TABLE OF CONTENT

/	GENERAL INFORMATION	Page 3
.1	Introduction	
.2	History	
.3	Committees	
L.4	Congress dates and location	
1.5	Venue	
6	Timetable	
2/	SCIENTIFIC PROGRAMME	Page 8
2.1	General Information	
2.2	Special sessions	
2.3	Awards	
2.4	Faculty	
2.5	Abstracts	
3/	REGISTRATION & ATTENDANCE	Page 16
3.1	Total attendance	
3.2	Attendance by country	
3.3	Attendance by region	
3.4	Delegates profile	
3.5	Continuing Medical Education (CME) Interests	
4/	INDUSTRY	Page 20
4.1	Exhibition	
4.2	Satellite Symposia	
4.3	Sponsorship and advertising	
5/	ANNEX	Page 22
5.1	Post congress survey	
6/	FCVB 2014	Page 27

1/ GENERAL INFORMATION

1.1 Introduction

Frontiers in CardioVascular Biology 2012 is the Second Meeting of the Council on Basic Cardiovascular Science (CBCS) of the European Society of Cardiology (ESC). The Council is composed of representatives from the ESC "basic" Working Groups and from non-ESC "basic" sister organisations.

8 ESC Working Groups:

Atherosclerosis and Vascular Biology Cardiac Cellular Electrophysiology Cardiovascular Pharmacology and Drug Therapy Cellular Biology of the Heart Coronary Pathophysiology and Microcirculation Development, Anatomy and Pathology Myocardial Function Thrombosis

And

6 Sister Societies:

Association for European CardioVascular Pathology (AECVP) European Vascular Biology Organisation (EVBO) European Council for Cardiovascular Research (ECCR) European Society for Microcirculation (ESM) European Atherosclerosis Society (EAS) International Society for Heart Research European Section (ISHR-ES)

Its second edition in London continued the ideals of the first meeting to bring the best and newest science to the cardiovascular arena. Within a wide-ranging programme, themes of Bioimaging, Degeneration and Regeneration, and Inflammation were highlighted. Invited speaker presentations, shorter talks selected from submitted abstracts, ensuring both the most recent data and strong involvement of younger speakers. Poster sessions were central in both position and timing. With travel bursaries and low early career registration fees, this was a meeting ideal for students and trainees.

1.2 History

FCVB 2010

16-19 July 2010 Berlin, Charité University Campus

FCVB 2012

30 March – 1 April 2012 London, Imperial College

1.3 Committees

Core Scientific Committee

Prof. Sian Harding FESC (GB) - Chairperson Prof. Axel Pries FESC (DE) Prof. Barbara Casadei FESC (GB) Prof. Raffaele De Caterina FESC (IT)

Programme Committee

WG Atherosclerosis and Vascular Biology Prof. R. Krams (GB) WG Cardiac Cellular Electrophysiology Prof. E. Cerbai FESC (IT) WG Cardiovascular Pharmacology and Drug Therapy Prof. K.P. Kjeldsen (DK) WG Cellular Biology of the Heart Dr. M. Ruiz-Meana (ES) WG Coronary Pathophysiology and Microcirculation Prof. C. De Wit (DE) WG Development, Anatomy and Pathology Prof. D.J. Henderson (GB) WG Thrombosis Prof. A. Siegbahn FESC (SE)

Scientific Advisory Committee

Prof. T. Aitman (GB) Prof. S. Bhattacharya FESC (GB) Dr. R.J. Hajjar (US) Prof. E.G. Kranias (US) Dr. J. Lepore (US) Prof. S. Moncada (GB)

Local Organising Committee

Prof. M. Avkiran Prof. A.H. Baker FESC Prof. M.R. Bennett Prof. D. Brook Prof. B. Casadei FESC Prof. D.A. Eisner Prof. D.J. Hausenloy FESC Prof. D.J. Henderson Prof. Lina Badimon FESC (ES) Prof. Jeremy Pearson (GB) Prof. Andrew Newby FESC (GB)

Association for European Cardiovascular Pathology Ass. Prof. A. Angelini FESC (IT) European Atherosclerosis Society Prof. P. Kovanen (FI) European Council for Cardiovascular Research Prof. M.J. Mulvany (DK) European Society for Microcirculation Prof. A. Shore (GB) European Vascular Biology Organisation Prof. I. Fleming (DE); Prof. S. George (GB) International Society for Heart Research -European Section Prof. T. Eschenhagen FESC (DE)

Prof. U. Ravens FESC (DE) Prof. M.D. Schneider FESC (GB) Dr. M.N. Sheppard (GB) Prof. D.J. Snyders (BE) Prof. G. Thiene FESC (IT) Prof. P.L. Weissberg FESC (GB)

Prof. M. Mayr Prof. A. Newby FESC Prof. D.E. Newby FESC Prof. S. Nourshargh Prof. J. Pearson Dr. C. Terracciano Dr. A. Williams Prof. I. Zachary

1.4 Congress dates and location

30 March – 1 April 2012

London Imperial College

1.5 Venue


London Imperial College

South Kensington Campus Exhibition Road, London SW7 2AZ, United Kingdom Web Site: www3.imperial.ac.uk






<u>Layout</u>




Imperial College London

Building floor plan



Imperial College Road



1.6 Timetable

2		F	RID	AY 30 MARCH	6		S/	٩TU	RDAY 31 M	IARCH				SU	NDAY 1 AF	PRIL	
07:30					07:30		-				07:30						07:30
08:00					08:00						08:00						08:00
08:30					08:30						08:30						08:30
09:00					09:00						09:00						09:00
09:30					09:30				-		09:30						09:30
10:00					10:00				SES	SIONS	10:00				SES	SIONS	10:00
10:30	R			WELCOME ADDRESS	10:30	R					10:30	R					10:30
11:00	Е			KEYNOTE	11:00	Е					11:00	Е					11:00
11:30	G				11:30	G			KEY	NOTE	11:30	G			KEY	NOTE	11:30
12:00				SESSIONS	12:00			E X	LUNCH		12:00			E X	LUNCH		12:00
12:30	S T	Ρ		SESSIONS	12:30	S T	Ρ	Ĥ	&	LUNCH	12:30	S T	Ρ	ĥ	&	LUNCH	12:30
13:00	R	0	Е		13:00	R	0	1	POSTER VIEWING	SYMPOSIUM	13:00	R	0	ï	POSTER VIEWING	SYMPOSIUM	13:00
13:30	Α	S T	X 	LUNCH &	13:30	Α	S T	в	VIEWING		13:30	Α	S T	в	VILVVING		13:30
14:00	Т	E	H	POSTER VIEWING	14:00	Т	E	I			14:00	Т	E	I.			14:00
14:30	I	R	B		14:30	I	R	T	SES	SIONS	14:30	I	R	Т	SES	SIONS	14:30
15:00	O N	S	T		15:00	O N	s	0			15:00	O N	s	 0			15:00
15:30	N		Т	SESSIONS	15:30	IN		N	COFFE	E BREAK	15:30	IN		N	COFFE	E BREAK	15:30
16:00			I		16:00						16:00				eee	SIONS	16:00
16:30			0	COFFEE BREAK	16:30				SES	SIONS	16:30				JE3	510113	16:30
17:00			N		17:00						17:00						17:00
17:30				SESSIONS	17:30						17:30				KEY	NOTE	17:30
18:00					18:00				KEY	NOTE	18:00				CLOSING	& AWARDS	18:00
18:30				OPENING CEREMONY	18:30						18:30						18:30
19:00				WELCOME	19:00						19:00						19:00
19:30				RECEPTION	19:30						19:30						19:30

2/ SCIENTIFIC INFORMATION

2.1 General Information

3

1

Lecture rooms

740 seats - Great Hall 230 seats - Clore Lecture Theatre 157 seats - Lecture Theatre 311

Poster area - set up for 167 posters/session

40 Sessions including:

- 35 Pre-arranged sessions:
 5 Keynote lectures
 25 Symposia (incl. 22 sessions with 1/2 oral abstract presentations)
 2 Lunch Symposia
 3 Special sessions (Opening Address, Opening Ceremony, Closing/Awards)
- Abstracts sessions:
 2 Oral abstracts sessions (YIA, Oral abstract session)
 3 Poster sessions (full day sessions)

625 Abstracts submitted

614 Abstracts validated for grading (625 – 11 withdrawn before grading)

565 Abstracts accepted for presentation (acceptance rate 92%)

- 51 oral
- 511 posters
- 35 withdrawn

137 Faculty members

243 Faculty roles

69 roles of Chairperson 88 roles of Speaker 86 roles of Other

2.2 Special Sessions

Keynote Lectures

Five high-profile keynote lectures delivered by world class leaders in their fields.

- Lessons in Science: competition in scientific research Prof. Salvador Moncada (London, GB)
- Endothelial metabolism: a target in angiogenesis.
 Prof. Peter Carmeliet (Leuven, BE)
- Gene regulation and blood flow.
 Prof. Peter Francis Davies (Philadelphia, US)
- Molecular imaging of the heart. Prof. Ron Heeren (Amsterdam, NL)
- Transdifferentiation of somatic cells into cardiomyocytes.
 Prof. Deepak Srivastava (San Francisco, US)

Keynote Lectures

Two sessions designed for Clinicians / Scientists interested in a deep understanding of thrombosis and antithrombotic therapy and basic researchers in the area of thrombosis and hemostasis.

- **Open hot issues on antiplatelet treatment in acute coronary syndromes.** The most advanced topics on antiplatelet treatment in acute coronary syndromes.
- **Coagulation and anticoagulation 2012 Basic and translational aspects.** The symposium will summarise current speculations on the different consequences in targeting various coagulation factors as antithrombotic strategies.

Opening Address

FCVB 2012 Chairperson Professor Sian E. Harding, FESC (London, GB)

Medical Director of the British Heart Foundation

Professor Peter L. Weissberg, FESC (London, GB) "The Continuing Challenge of Vascular Biology"

CBCS Chairman

Professor Axel R. Pries, FESC (Berlin, DE)

Opening Ceremony

Introduction by CBCS Chairman

Professor Axel R. Pries, FESC (Berlin, DE)

ESC Secretary/Treasurer Professor David A. Wood, FESC (London, GB) "ESC and advocacy for basic science"

Welcome Address by FCVB 2012 Chairperson

Professor Sian E. Harding, FESC (London, GB)

Opening Address by CBCS Chairman Professor Axel R. Pries, FESC (Berlin, DE)

Closing Ceremony & Awards

Chairpersons: A.R. Pries (Berlin, DE); S.E. Harding (London, GB)

Young Investigator Awards

M. Mulvany (Aarhus, DK); A. Koller (Pecs, HU) Distributed by the European Council for Cardiovascular Research & the European Society for Microcirculation (Awardees and finalists as below)

Best Poster Awards

A.R. Pries (Berlin, DE) Distributed by the ESC Council on Basic Cardiovascular Science (Awardees and finalists as below)

Investigative Pathology in Cardiovascular Diseases Award

P. Bruneval (Paris, FR) Distributed by the Association for European Cardiovascular Pathology (Awardees and finalists as below)

Oral & Poster Awards

E. Cerbai (Florence, IT); P.G.A.Volders (Maastricht, NL) Distributed by the ESC WG on Cardiac Cellular Electrophysiology (Awardees and finalists as below)

Travel grant awardees

Closing remarks

2.3 Awards

Young Investigator Awards

Winner:

Miss Meiser Maxie (Homburg, DE) Title: Mitofusin 2 controls calcium transmission between the SR and mitochondria and regulates the bioenergetic feedback response in cardiac myocytes

Runner-Ups:

Doctor Schroen Blanche (Maastricht, NL)

Title: Absence of microRNA-155 protects against adverse cardiac inflammation and hypertrophy during pressure overload and prevents heart failure

Miss Lunde Ida Gjervold (Oslo, NO)

Title: Syndecan-4, a z-disc proteoglycan, regulates mechanical stress-induced, pro-hypertrophic NFAT signaling in cardiomyocytes through a direct interaction with calcineurin

Finalists:

Mrs Stapel Britta (Hannover, DE) Title: Cardiac STAT3 deficiency is a pre-disposition for heart failure in response to beta-adrenergic stimulation

Doctor Paavola Jere (Espoo, FI)

Title: PKD2 mutations lead to impaired calcium cycling in the heart and predispose to heart failure

Doctor Robinson Paul (Oxford, UK)

Title: Cardiomyopathy-causing mutations in cardiac thin filament regulatory proteins acutely affect Ca2+ buffering and Ca2+ dependent signalling in situ.

Best Poster Awards

Distributed by the ESC Council on Basic Cardiovascular Science

Winners:

P83 - G. Foldes - Transplantation of human embryonic stem cell-derived endothelial cells into rats: a new approach for vascular regeneration

P199 - J Ritterhoff - S100A1 gene therapy protects cardiomyocytes against pro-arrhythmogenic Ca2+ waves and after-contractions

P311 - K. Hamesch - The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation after arterial injury without impairing re-endothelialisation

P429 - S. Prapa - Biomechanical perspectives of thoracic aortic aneurysm formation in patients with a bicuspid aortic valve: an integrated analysis

P477 - N. Smart - An essential role for thymosin beta 4 in regulating vascular smooth muscle cell development and adult vessel stability.

P554 - PJM Wijnker - Impact of site specific phosphorylation of the protein kinase A sites Ser23 and Ser24 of cardiac troponin I on contractile function in human cardiomyocytes

Investigative Pathology in Cardiovascular Diseases Award

Distributed by the Association for European Cardiovascular Pathology **Winners:**

P589 - PAJ Krijnen - Loss of DPP4 activity is related to a pro-thrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients.

Oral & Poster Awards

Distributed by the ESC WG on Cardiac Cellular Electrophysiology

Winners:

Oral: 458 – C. Ferrantini - Action potential propagation in transverse-axial tubular system is impaired in heart failure

Poster: P537 – IA. Ghouri - Characterisation of electrical activity in the infarct region of rat hearts using widefield epifluorescence and 2-photon excitation techniques

2.4 Faculty

Activities

	203	LO	20	012
	Roles	Roles Persons		Persons
Chairperson	125	86	69	56
Speaker	90	85	88	87
Other (judges, reviewers,)	N/A*	N/A*	86	82
Total	215	171	243	137

* Abstract judges in FCVB 2010 were registered under Chairpersons roles.

Role distribution

# Roles	2010	2012
1	N/A	51
2	N/A	69
3	N/A	14
4	N/A	3
Total	N/A	137

2.5 Abstracts

General information

	2010	2012	+/- 2010
Submitted	463	625	+ 158
Withdrawn	18	11	- 7
Accepted for presentation	437	565	+ 128
- oral	16	51	+19
- poster	421	511	+106
- withdrawn	20	35	+15
% acceptance	94%	92%	-1%
Presented	371	477	+106 (+28%)

<u>By Topic</u>

Topic name	Accepted	Withdrawn	Presented
Biomarkers	25	1	19
Therapeutic approaches / Nanomedicine / Gene therapy	22		17
Gene analysis	17	2	10
Electrophysiology / Arrhythmias	40	2	34
Atherosclerosis	22	1	18
Cell differentiation / Proliferation	18		15
Cytokines / Inflammation	15	1	11
Ion channels / Ion exchangers and pumps	8	1	4
Ischaemia / Reperfusion	44	3	39
Stem cells and cell therapy	34	1	31
Inflammation / Leucocytes	18	2	14
Lipids	9	1	6
Cardiomyopathies / Mechanisms	32		31
Smooth muscle	17		16
Neurohormones	13	1	11
Diagnostic approaches / Molecular imaging	11		10
Fibroblasts / Fibrosis / Matrix	11		10
Mitochondria	12	1	10
Animal models	9		8
Cell death / Apoptosis / Autophagy	9	2	6
Microcirculation	9	3	5
Developmental genetics	5		4
Proteomics / Metabolomics / Lipidomics / Glycomics	6	1	4
Thrombosis and platelets	7	2	4
Transcriptional control	4		3
Computer modelling / Bioinformatics	3		2

Angiaganasis	10		10
Angiogenesis	19		19
Hypertrophy	19		19
Calcium fluxes	12	1	11
Endothelium	12	2	10
Pathology	9		9
Mechanotransduction	8		8
Morphogenetic mechanisms	7		7
Contractile apparatus	6		6
Haemostasis	7	1	6
Non-coding RNA	6		6
Control mechanisms	7	2	5
Cytoskeleton / Cytoarchitecture	5		5
Energetics	5		5
Growth factors	5		5
Nitric oxide / Reactive oxygen species	7	2	5
Aging	4		4
Hibernation / Preconditioning / Stunning	2		2
Tissue engineering	3	1	2
Oxygen sensing	1		1
Gender	1	1	
Grand Total	565	35	477

Top 10 Countries (by accepted)

Country		2010		2012			
Country	Submitted	Accepted	Presented	Submitted	Accepted	Presented	
United Kingdom	44	41	N/A	132	124	113	
Germany	97	93	N/A	66	64	54	
Italy	55	54	N/A	44	44	36	
Spain	21	20	N/A	39	39	37	
France	10	9	N/A	26	25	22	
Netherlands	15	15	N/A	36	35	33	
Russian Federation	15	15	N/A	40	26	13	
Belgium	10	10	N/A	16	15	15	
Hungary	19	17	N/A	15	15	12	

Evolution of abstract based programme by country representation (by presented abstracts)

Country	Accepted	No show	Withdrawn	Presented
United Kingdom	124	5	6	113
Germany	64	4	6	54
Spain	39	2		37
Italy	44	4	4	36
Netherlands	35	2		33
France	25	2	1	22
Belgium	15		-	15
Russian Federation	26	9	4	13
Hungary	15	2	1	12
Austria	10	_	-	10
Brazil	10			10
Greece	10			10
Switzerland	9			9
United States of America	9	1		8
Czech Republic	8			8
Portugal	8			8
	8	1		
Japan Norway	8	1		7
· · · · · · · · · · · · · · · · · · ·	7			
Poland		1		6
Taiwan	6		-	6
Finland	6		1	5
Thailand	5			5
Sweden	5		1	4
Denmark	4			4
Belarus	4		1	3
Romania	4	1		3
Luxembourg	3			3
Slovak Republic	3			3
no info	3			3
Ukraine	9	7		2
Canada	4	1	1	2
Korea, Republic of	2			2
New Zealand	2			2
Serbia	2			2
Bulgaria	5		4	1
China, People's Republic of	2	1		1
Nigeria	2	1		1
Argentina	1			1
Indonesia	1			1
Ireland	1			1
Lithuania	1			1
Moldova, Republic of	1			1
Qatar	1			1
Tunisia	1			1
India	4	2	2	0
Iran (Islamic Republic of)	3	2	1	0
Israel	1	_	1	0
Latvia	1	1	-	0
Pakistan	1	-	1	0
Turkey	1	1	<u>_</u>	0
Georgia	2	2		0

3/ REGISTRATION & ATTENDANCE

3.1 Total attendance

	2010	2012	+/- 2011
Active delegates	682	866	+186 (+27%)
Scientists	332	405	+73 (+22%)
Students	137	204	+67 (+49%)
Faculty (free)	124	153	+29 (+23%)
Travel Grants	38	57	+19 (+50%)
Day Tickets	38	39	+1 (+2%)
Other (free)	9	4	-5 (-55%)
Press (free)	4	4	+0 (+0%)
Exhibitors	6	45	+39 (+750%)
Accompanying persons	12	No more acc. persons	N/A
Total Participants	700	911	+211 (+30%)

3.2 Attendance by Country

Top 10 attending countries

2010		2012			
Germany	162	United Kingdom	238		
Greece	78	Germany	90		
United Kingdom	62	Italy	69		
Italy	60	Netherlands	67		
Spain	39	Greece	61		
Netherlands	27	Spain	43		
Belgium	22	France	39		
United States of America	22	Belgium	28		
France	20	Russian Federation	24		
Hungary	20	Sweden	17		

Number of attending delegates per country

	2010	2012	2012 % of Total
Argentina	1	1	0,1%
Australia	6	0	0,0%
Austria	12	15	1,7%
Belarus	1	3	0,3%
Belgium	22	28	3,2%
Bosnia & Herzegovina	1	0	0,0%
Brazil	3	6	0,7%
Bulgaria	0	4	0,5%
Canada	7	3	0,3%
China, People's Republic of	2	1	0,1%
Czech Republic	9	8	0,9%

Denmark	5	9	1,0%
Estonia	1	0	0,0%
Finland	4	11	1,3%
France	20	39	4,5%
Germany	162	90	10,4%
Greece	78	61	7,0%
Hong Kong	2	0	0,0%
Hungary	20	14	1,6%
India	0	1	0,1%
Indonesia	1	1	0,1%
Iran (Islamic Republic of)	5	0	0,0%
Ireland	0	1	0,1%
Israel	3	2	0,2%
Italy	60	69	8,0%
Japan	1	10	1,2%
Korea, Republic of	3	1	0,1%
Latvia	4	3	0,3%
Lithuania	0	1	0,1%
Luxembourg	0	4	0,5%
Moldavia	0	1	0,1%
Netherlands	27	67	7,7%
New Caledonia	1	0	0,0%
New Zealand	0	4	0,5%
Nigeria	2	0	0,0%
Norway	15	14	1,6%
Palestine	2	0	0,0%
Poland	14	6	0,7%
Portugal	5	11	1,3%
Qatar	0	1	0,1%
Romania	4	2	0,2%
Russian Federation	5	24	2,8%
Saudi Arabia	2	1	0,1%
Serbia	0	2	0,2%
Singapore	1	0	0,0%
Slovak Republic	2	3	0,3%
Slovenia	1	0	0,0%
South Africa	2	0	0,0%
Spain	39	43	5,0%
Sweden	12	17	2,0%
Switzerland	17	14	1,6%
Taiwan, ROC	2	7	0,8%
Thailand	0	4	0,5%
Tunisia	0	1	0,1%
Turkey	9	1	0,1%
Ukraine	0	2	0,1%
United Kingdom	62	238	27,5%
United States of America	22	16	1,8%
Uzbekistan	0	10	0,1%
Venezuela	1	0	0,1%

3.3 Attendance by Region

Number of attending delegates per region

	2010	2012
Africa	4	0
Asia Pacific	28	32
ESC countries	614	808
North America	29	19
South & Central America	5	7
Total	680	866 (+27%)

3.4 Delegates profile

91% of FCVB 2012 attendees have provided Field of Interest information. (Multiple choices)

Interests and Areas of Expertise	%
Basic Science	81,0%
Heart Failure (HF)	45,5%
Myocardial Disease	31,9%
Genetics	22,3%
Chronic Ischaemic Heart Disease (IHD)	21,5%
Acute Coronary Syndromes (ACS)	20,5%
Hypertension	19,5%
Arrhythmias	18,3%
Congenital Heart Disease	15,3%
Diabetic Heart Disease	14,9%
Non-invasive imaging - Echocardiography, CMR, CT and Nuclear Techniques	12,9%
Clinical Pharmacology	11,9%
Atrial Fibrillation	11,0%
Other	9,9%
Peripheral Arterial Diseases	9,5%
Sudden Cardiac Death and Resuscitation	8,6%
Valvular Heart Diseases	8,2%
Cardiovascular Rehabilitation and Secondary Prevention – Long-term Management	7,6%
Invasive imaging - Cardiac Catheterisation and Angiography	7,3%
Interventional Cardiology	5,5%
Diseases of the Aorta and Trauma to the Aorta and Heart	5,1%
Thromboembolic Venous Disease	4,7%
Primary Pulmonary Hypertension (PPH)	4,6%
Rehabilitation and Exercise Physiology	4,0%
Syncope	3,6%
Pregnancy and Heart Disease	3,2%
Cardiac Tumours	2,9%
Infective Endocarditis	2,9%
Pericardial Disease	2,7%
Cardiac Consult	1,2%

90% of FCVB 2012 attendees have provided this information. (Multiple choices)

Place Of Work	%
Research	66,1%
In University Hospital	50,5%
In Non-University Hospital	3,7%
Private Practice	3,1%
Other	2,3%

91% of FCVB 2012 attendees have provided Professional Activity information. (Single choice)

Professional Activity	%
Scientist	68,4%
Cardiologist	16,4%
Other	8,3%
Cardiologist - Trainee	3,6%
Surgeon	1,3%
Technician	0,6%
Industry/Agent	0,4%
Press/Medical Writer	0,4%
General Practitioner	0,3%
Public Health Organisation/NGO	0,3%
Nurse	0,1%
PR Agency/Comms	0,0%

3.5 Continuing Medical Education (CME) Interests


68% of of FCVB 2012 attendees have provided this information (optional). (Multiple choices)

CME Interests	%
Congresses and Meetings	87,9%
Scientific Journals and Publications	81,4%
Online Education	42,0%

4/ INDUSTRY

4.1 Exhibition

Number of stands: 16 in total (ESC stand included) Number of exhibitor badges: 45 in total



Exhibitor	Booth size
Athera Biotechonologies AB	9m²
Aurora Scientific Inc	9m²
Cairn Research Ltd	9m²
Data Sciences International	9m²
European Society of Cardiology	9m²
IonOptix Europe	9m²
Moor Instruments	9m²
Nanion Technologies	9m²
Oxford University Press	9m²
PromoCell GmbH	9m²
Radnoti Ltd	9m²
Scientifica	2m²
Seahorse Bioscience	9m²
Thermo Fisher Scientific	9m²
Wisepress Medical Bookshop	6m²
World Precision Instruments	9m²
Total	134m ²

Comparison with 2010

Company	2010 (m²)	2012 (m²)	+/- 2010 (m²)
AD Instruments GmbH	9		-9
Athera Biotechnologies AB		9	+9
Aurora Scientific Inc		9	+9
Cairn Research Ltd		9	+9
Data Sciences International		9	+9
European Society of Cardiology	9	9	=
IonOptix Europe	9	9	=
Moor Instruments		9	+9
Multi Channel Systems	9		-9
Nanion Technologies		9	+9
Oxford University Press	9	9	=
PromoCell GmbH		9	+9
Radnoti Ltd		9	+9
Scientifica		2	+2
Seahorse Bioscience		9	+9
Thermo Fisher Scientific		9	+9
Wisepress Medical Bookshop		6	+6
World Precision Instruments		9	+9
Total	45	134	+89

4.2 Satellite Symposia

No satellite symposia

4.3 Sponsorship & advertising

AstraZeneca Bayer BMS Boehringer Ingelheim British Heart Foundation Carl Zeiss Ltd Servier Wolters Kluwer

5/ ANNEX

5.1 Post congress survey

726 participants received this survey, 119 responded (16 %)

Q1. Was this your first time at FCVB?

Yes: 87,6 % No: 12,4 %

Q2. How did you learn about this congress?

Recommended by a friend or colleague	35,8%
Through the ESC Web Site	22,5%
Email from the organiser	20%
Attended Previous congress	10%
Through another Web Site (please specify in comment)	7,5%
At another conference (please specify in comment)	2,5%
Promotional brochure	0,8%
In the news (Journal, Radio)	0%

Other:

- Was invited to speak (6)
- Marie Curie SmArt ITN Web Site
- Through my WG (DAP)

Q3. Is the accreditation (EBAC/CME credits) an important factor for attending the congress?

Yes: 81% No: 19%

Q4. Would you say you improved your scientific knowledge at the congress?

Yes: 99,2 % No: 0.8%

Q5. What format of sessions are of most interest to you?

72,7%
68,6%
58,7%
43,8%
13,2%
2,5%
1,7%

Other:

- A 'key-opinion leaders' debate. I was a bit disappointed on the lack of questions/debate after keynote lectures (also due to time limitations).

Q6. Which of the following FCVB 2012 main topics were of most interest to you?

Cardiac turnover and regeneration	45%
Vascular remodelling in ageing and disease	33,3%
Novel bioimaging methods in cardiac and vascular tissues	33,3%
Cytoskeleton, extracellular matrix and mechanosensing	33,3%
Lipids, atherosclerosis and microcirculation	28,3%
Therapeutic targets in cardiac calcium handling	27,5%
Developmental and stem cell biology	25,8%
The immune system and atherosclerosis	25%
Genetics, epigenetics and genomics	25%
Molecular imaging in atherosclerosis	19,2%
Mitochondrial biogenesis and cellular energy sensors	17,5%
Subcellular events in arrhythmia genesis	15%

Q7. Please rate the following in terms of fulfilling your expectations:

	Very poor	Poor	Average	Good	Excellent
Scientific Programme	0,8%	0%	8,3%	44,6%	46,3%
Poster content	0%	0,8%	14,9%	55,4%	28,9%
Exhibition	0,8%	6,6%	46,3%	41,3%	5%
Congress venue	1,7%	4,1%	29,8%	37,2%	27,3%
Interaction with the organizers (e.g. Registration/On-site)	0%	1,7%	14%	51,2%	33,1%
Lunches and coffee breaks	7,4%	10,7%	27,3%	41,3%	13,2%
Get Together evening	4,1%	3,3%	36,4%	47,9%	8,3%
London as a destination	0%	0%	3,3%	36,4%	60,2%

Q8. What is your background/occupation?

Basic researcher	75,8%
Clinical researcher	10%
Clinician	7,5%
Other	6,7%

Other:

- Editor
- Both basic researcher and clinician (4)
- Cardiovascular pathologist (physician)
- Translational researcher (Background in Medicine and Biology)
- Genetician

Q9. What general topic is of most interest to you?

Basic Science	59,2%
Translation from bench to beside	32,5%
Clinical cardiology	5,8%
Other	2,5%

Other:

- Both clinical cardiology and basic science
- Translational science; from bedside to bench
- Heart physiology

Q10. Are you a member of an ESC Working Group or Sister Society of the Council on Basic Cardiovascular Science?

None	53,3%
ISHR - International Society for Heart Research European Section	8,3%
ESC WG Cellular Biology of the Heart	5,8%
ESC WG Cardiac Cellular Electrophysiology	5,8%
ESC WG Atherosclerosis and Vascular Biology	5%
ESC WG Development, Anatomy & Pathology	5%
ESC WG Myocardial Function	5%
ESC WG Thrombosis	4,2%
AECVP - Association for European Cardiovascular Pathology	1,7%
EAS - European Atherosclerosis Society	1,7%
ESC WG Coronary Pathophysiology & Microcirculation	1,7%
ESM - European Society for Microcirculation	0,8%
EVBO - European Vascular Biology Organisation	0,8%
ESC WG Cardiovascular Pharmacology and Drug Therapy	0,8%
ECCR - European Council for Cardiovascular Research	0%

Q11. Comments (scientific)

- Well run and organised with an excellent scientific program
- The keynote speakers were all excellent very engaging and great presentation (2)
- The lunch-time symposium was very well-organised, with very excellent speakers
- The quality and quantity of science and the variety of research areas covered was really great
- The poster sessions were very good where the moderators and attendants came to share the opinions.
- Would be good to see more oral presentations with fresh scientific results (ideally unpublished) and less review talks (2)
- Keynote speakers titles didn't tend to reflect the topics!
- Presentations were too long (3)
- At some sessions, which were quite predictable to become popular (especially the one on miRNAs), many people had to stand in the aisle or sit on the stairs. You don't expect that for such a registration fee (2)
- Better organise the schedule of parallel sessions. It always seemed that some slots included 2 or 3 sessions of interest while occasional sessions had none
- Would benefit from more oral abstract presentations. Keynote/plenary lectures were very good, but it was a shame they did not allow questions at the end
- As my main focus is on lipids in atherosclerosis I found the scientific content on that specific subject rather limited, also because a number of posters on that subject withdrew and there was no symposium on that subject
- Possible small number of selected practical workshop sessions

- It is now the second time I attended and the format does not work. The sessions are erratically compiled topics without coherence and thorough thought. I find the time to suggest topics from within the working groups to short; hence those sessions appear to remain which have been put forward by experience ESC members. The topics are unimaginative and certainly not cutting edge. Many key researchers from Europe are not extending. Even Londoners, scheduled to chair sessions, did not show up. Most speakers appear and disappear. The meeting format is simply not working. In turn I suggest to put strong research leaders in charge to compile the program, with personal bias and full risk.
- Poster sessions were too rushed (2)
- The session about Ageing/Vascular health (Sunday morning) was not good
- More translational research / clinical application of research
- More cardiac muscle physiology would be nice
- More attention shall be given to the pathogenesis of vascular aneurysms and dissections in the next FCVB meeting
- More sessions on Epigenetics (2)
- From the heart failure point of view the meeting was heavily weighted towards acute heart failure and myocardial infarction. There was little or no discussion of chronic heart failure, which is surprising considering the therapeutic need in this area
- A specific session for cardiac metabolism should be added
- More keynote lectures (2)
- Should include posters/talks in the section on cytoskeleton on role of microtubules in cardiac disease.
- More emphasis on the role of vascular dysfunction as a mechanism of myocardial infarction or other myocardial abnormalities could be of significant interest to the vascular researchers. Devoting an entire session to this area would enhance our knowledge as to how vascular and cardiac tissue interact in normal heart as well as in pathological situations. Relative role of specific mechanisms leading to endocardial endothelial interaction in disease states could be of significant interest.
- Encourage more young talent through travel awards and more poster awards.
- More of: general genetics, perhaps a session about genomewide studies i CVD, a session about 'new' whole genome techniques such as next generation sequencing, RNA sequencing, different tyupes of arrays, GWAs etc and how these transtlate into more personalised medicine the clinic.

Q12. Would you attend the next FCVB meeting in Barcelona (4-6 July 2014)?

Yes: 59,2 % No: 4,2 % Undecided: 36,1 %

